Welcome to our dedicated page for Senti Bioscience SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Senti Biosciences鈥� latest 10-K can feel like decoding DNA鈥攈undreds of pages packed with Gene Circuit schematics, CAR-NK manufacturing notes, and detailed clinical-trial risk factors. Tracking burn-rate assumptions or pinpointing whether executives just bought shares is time-consuming, even for seasoned analysts.
Stock Titan solves that problem. Our AI parses every disclosure the moment it hits EDGAR, delivering Senti Biosciences SEC filings explained simply. Need the story behind a sudden 8-K? You鈥檒l see the material event in plain English, plus links to supporting exhibits. Curious about cash runway? The Senti Biosciences quarterly earnings report 10-Q filing arrives with instant ratios and year-over-year comparisons. Watching insider confidence? Get alerts for Senti Biosciences Form 4 insider transactions real-time. Key resources include:
- Senti Biosciences insider trading Form 4 transactions with sortable tables
- Senti Biosciences annual report 10-K simplified鈥攖rial milestones, funding needs, risk summaries
- Senti Biosciences proxy statement executive compensation decoded for pay鈥損erformance alignment
- Senti Biosciences 8-K material events explained alongside market-moving context
Because the company sits at the frontier of synthetic biology, investors care about how Gene Circuit logic gates translate into safety claims, when Phase 1 data might read out, and whether insider buying supports the narrative. Our AI-powered summaries, real-time filing updates, and expert analysis turn those complex disclosures into clear signals. From Senti Biosciences earnings report filing analysis to understanding Senti Biosciences SEC documents with AI, every document is one click away鈥攕o you can act on facts, not guesswork.
Celadon Partners disclosed a 45.0% beneficial ownership stake in Senti Biosciences, Inc. (SNTI), reporting ownership of 13,404,441 shares, which includes 3,627,441 shares issuable upon exercise of warrants subject to a 45% ownership cap. The percentage is calculated using 26,160,206 shares outstanding as of July 31, 2025. The filing (Amendment No. 2 to Schedule 13D) states Celadon intends to continue preliminary discussions with Senti about a potential financing and may seek changes to capital structure and Board composition, including potential additional Board representation. Celadon also reserves the right to buy or sell securities or pursue hedging or other actions as circumstances evolve.
Event: Senti Biosciences, Inc. (SNTI) filed a Form 4 reporting that director James J. Collins was granted 21,950 stock options on 06/25/2025.
Terms of the option: the exercise price is $2.05 per share, with 100 % of the underlying shares vesting on the earlier of (i) the first anniversary of the grant date or (ii) the company鈥檚 2026 annual meeting, provided Mr. Collins remains in service until that date. The options expire on 06/24/2035.
Ownership impact: Following this grant, Collins directly holds 21,950 derivative securities (options) and no non-derivative transactions were reported. No shares were sold or otherwise disposed of in this filing.
Sign-off: The filing was executed by attorney-in-fact Timothy Lu and dated 06/27/2025.
Form 4 overview: On 06/25/2025, Senti Biosciences (ticker SNTI) reported granting director Feng Hsiung a stock option for 21,950 common shares at an exercise price of $2.05 per share.
The option, filed on 06/27/2025, vests 100 % on the earlier of (i) the first anniversary of the grant or (ii) the 2026 annual shareholders鈥� meeting, subject to continued board service. It carries a 10-year term with an expiration date of 06/24/2035.
No open-market purchase or sale of common shares occurred; the transaction is strictly an equity-based compensation award. After the grant, Mr. Hsiung beneficially owns 21,950 derivative securities, and the filing shows no change to his direct or indirect ownership of outstanding common shares. The disclosure does not reference a Rule 10b5-1 trading plan.
Investor take-away: This is a routine director compensation event that modestly aligns board incentives with shareholder value. It creates potential dilution only if exercised and has no immediate impact on cash flow, operations, or the company鈥檚 financial outlook. The Form 4 contains no earnings or operational data.
Senti Biosciences director Fran Schulz received a stock option grant on June 25, 2025. The grant consists of 21,950 options to purchase common stock at an exercise price of $2.05 per share.
Key terms of the option grant:
- Exercise price: $2.05 per share
- Expiration date: June 24, 2035
- Vesting schedule: 100% vests at earlier of (i) first anniversary of grant date or (ii) 2026 Annual Meeting
- Vesting contingent on continued service through applicable date
The Form 4 was filed by Robert Cutler as attorney-in-fact on June 27, 2025. This transaction represents standard non-employee director equity compensation and aligns the director's interests with shareholders through long-term stock ownership potential.
FAQ
What is the current stock price of Senti Bioscience (SNTI)?
What is the market cap of Senti Bioscience (SNTI)?
